產(chǎn)品目錄

規(guī)格	5mg 10mg 50mg 100mg
CAS	1055986-67-8
別名	N/A
化學(xué)名	N/A
分子式	C23H21N5O3S.xHCl
分子量	N/A
溶解度	Soluble in DMSO
儲(chǔ)存條件	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request

產(chǎn)品描述：

Amuvatinib hydrochloride (MP470 hydrochloride) is a multi-targeted receptor tyrosine kinases inhibitor, which inhibits c-Kit (D816V), c-Kit (D816H), c-Kit (V560G), c-Kit (V654A), PDGFRα (D842V), and PDGFRα (V561D) with IC50s of 950 nM, 10 nM, 34 nM, 127 nM, 81 nM, and 40 nM, respectively[1]. Antineoplastic activity[2].

MP470, a novel receptor tyrosine kinase (RTK) inhibitor has shown growth inhibitory activity against a variety of cancer cell lines. MP470 is effective on LNCaP and PC-3 cells with an IC50 of ~4 μM and 8 μM, respectively. When Erlotinib (10 μM) is combined with varying doses of MP470, the IC50 of MP470 decreased to 2 μM on LNCaP cells[2]. Akt activity (as measured by phosphorylation on Ser473) is significantly reduced by 10 μM MP470 alone but is not reduced by Erlotinib or Imatinib Mesylate (IM). Moreover, MP470 plus Erlotinib completely abolished Akt phosphorylation in LNCaP cells with an unchanged total protein level of Akt[2].

Four LNCaP xenograft arms each with 12 mice are dosed intraperitoneally with DMSO (control) or Erlotinib 80 mg/kg or MP470 50 mg/kg or Erlotinib 80 mg/kg plus MP470 50 mg/kg daily for 2 weeks and then observed for a further 11 days. Individual therapy with MP470 or Erlotinib shows modest tumor growth inhibition (TGI), while MP470 plus Erlotinib has a marked effect on TGI (45-65%). However, due to the high doses of MP470 used, only five or one mouse remained alive in the combination arm at the end of treatment or at the end of the study, respectively. Therefore the MP470 dose is reduced to 10 mg/kg or 20 mg/kg for the combination treatment. TGI in the group receiving 10 mg/kg MP470+80 mg/kg Erlotinib is not significantly different from the control group. However, mice receiving 20 mg/kg MP470+80 mg/kg Erlotinib have a significant TGI compared to the control group (p=0.01)[2].

[1]. David J. Bearss, et al. Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same. US20080226747A1. [2]. Qi W, et al. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer. 2009 May 11;9:142.

特別提醒：

1. 本產(chǎn)品僅供科研使用。請(qǐng)勿用于醫(yī)藥、臨床診斷或治療，食品及化妝品等用途。請(qǐng)勿存放于普通住宅區(qū)。

2. 為了您的安全和健康，請(qǐng)穿好實(shí)驗(yàn)服并佩戴一次性手套和口罩操作。

原創(chuàng)作者：上海莼試生物技術(shù)有限公司

在線(xiàn)咨詢(xún)

留言注意事項(xiàng)：

1.遵守中華人民共和國(guó)有關(guān)法律、法規(guī)，尊重網(wǎng)上道德，承擔(dān)一切因您的行為而直接或間接引起的法律責(zé)任。

2.請(qǐng)您真實(shí)的反映產(chǎn)品的情況,不要捏造、誣蔑、造謠。如對(duì)產(chǎn)品有任何疑問(wèn),也可以留言咨詢(xún)。

3.未經(jīng)本站同意，任何人不得利用本留言簿發(fā)布個(gè)人或團(tuán)體的具有廣告性質(zhì)的信息或類(lèi)似言論。

您感興趣的產(chǎn)品*
您的單位*
聯(lián)系人*
聯(lián)系電話(huà)*
詳細(xì)地址*
常用郵箱*
請(qǐng)輸入您對(duì)我們的意見(jiàn)或建議*
驗(yàn)證碼*

同類(lèi)產(chǎn)品

Pericosine A GIP, human TFA Syk-IN-1 IRAK4-IN-6 Rogaratinib (BAY1163877) Pyrotinib (SHR-1258) GSK1838705A Pertuzumab Lenvatinib mesylate GNE-7915 tosylate

訂購(gòu)流程

訂貨流程

產(chǎn)品訂購(gòu)說(shuō)明:

1、報(bào)價(jià)含普票、運(yùn)費(fèi)。

2、常用試劑備貨充足，除對(duì)溫度要求極其嚴(yán)格的產(chǎn)品當(dāng)天可發(fā)貨。

3、進(jìn)口原裝產(chǎn)品要3-6周的貨期，詳細(xì)情況請(qǐng)咨詢(xún)客服。

4、訂貨時(shí)間為工作日每周一至周五16:00之前。

5、如需代為檢測(cè)，標(biāo)本對(duì)環(huán)境溫度高，可聯(lián)系客服安排專(zhuān)人取樣（限省內(nèi)客戶(hù)）。

6、代測(cè)免收代測(cè)費(fèi)，一周出結(jié)果。

7、產(chǎn)品因運(yùn)輸途中包裝破損請(qǐng)拒絕簽收，做退回。我們將在24小時(shí)之內(nèi)為您補(bǔ)發(fā) 損壞產(chǎn)品。

8、如因單位財(cái)務(wù)制度原因，可申請(qǐng)先發(fā)貨，報(bào)賬后付款（此條款僅限醫(yī)院、學(xué)校信譽(yù)良好客戶(hù)）。

付款方式

普票匯款信息

賬戶(hù) 名：上海生物

開(kāi) 戶(hù) 行：中國(guó)銀行山東省分行營(yíng)業(yè)部

賬號(hào)：2169 2341 6278

為方便廣大客戶(hù)辦理貨款我公司提供多個(gè)銀行的賬戶(hù)，學(xué)校、醫(yī)院客戶(hù)購(gòu)買(mǎi)產(chǎn)品如因單位財(cái)務(wù)制度原因可先發(fā)貨待報(bào)賬后匯款，請(qǐng)及時(shí)告知銷(xiāo)售人員已做具體操作。